GlassScriptPhysician profile
Sun H Jones
NPI 1124091756
$2,441.43
in general payments reported to CMS, 2019-2025
31 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $604 · 2023: $444 · 2024: $453 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $473.03 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.49 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.17 | 2021-2023 | |
| Amgen INC. | $166.60 | 2023-2025 | Evenity, Prolia |
| Abbott Laboratories | $158.24 | 2021-2024 | Mitraclip, Octrode |
| Novo Nordisk INC | $156.56 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $131.01 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Novartis Pharmaceuticals Corporation | $81.80 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $80.83 | 2025 | Invega Sustenna |
| Sumitomo Pharma America, INC. | $78.01 | 2025 | Gemtesa |
| Abbvie INC. | $66.77 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $60.34 | 2021-2024 | Breztri |
| Boston Scientific Corporation | $55.83 | 2022-2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $55.76 | 2021-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $49.19 | 2021-2023 | Verquvo, Belsomra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $47.89 | 2021 | |
| Eisai INC. | $40.35 | 2021 | |
| Pfizer INC. | $38.65 | 2022-2023 | |
| Redhill Biopharma INC. | $33.96 | 2021-2024 | Talicia |
| Sanofi Pasteur INC. | $33.78 | 2022-2023 | |
| Nevro Corp. | $23.10 | 2022 | |
| Biotronik INC. | $22.19 | 2021 | |
| Optinose US, INC. | $21.03 | 2025 | |
| Teleflex LLC | $19.23 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.99 | 2023 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $18.31 | 2022 | |
| Axonics, INC. | $18.26 | 2023 | Axonics |
| Lundbeck LLC | $16.10 | 2023 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $15.53 | 2022 | |
| Lucid Diagnostics INC. | $12.37 | 2022 | |
| Currax Pharmaceuticals LLC | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sun Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.